| P50 | author | Jose Angel Ruiz-Ortega | Q60326756 |
| | Luisa Ugedo | Q42813298 |
| P2093 | author name string | Gurutz Linazasoro | |
| | Teresa Morera-Herreras | |
| P2860 | cites work | The endocannabinoid system as an emerging target of pharmacotherapy | Q24648473 |
| | Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 |
| | Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata | Q28377147 |
| | Two opposite effects of Delta(9)-tetrahydrocannabinol on subthalamic nucleus neuron activity: involvement of GABAergic and glutamatergic neurotransmission | Q28580826 |
| | Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 |
| | Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q44237885 |
| | Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism | Q44418544 |
| | Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia | Q44451116 |
| | Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 |
| | Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model | Q44933218 |
| | The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice | Q45087565 |
| | Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 |
| | High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. | Q46456086 |
| | Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function | Q48262881 |
| | Response characteristics of subthalamic neurons to the stimulation of the sensorimotor cortex in the rat. | Q48301727 |
| | Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent | Q48332786 |
| | Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 |
| | Burst and oscillation as disparate neuronal properties | Q48901690 |
| | Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. | Q51976878 |
| | Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. | Q52060269 |
| | Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop | Q56093340 |
| | Subthalamic neuron activity related to tremor and movement in Parkinson's disease | Q64774331 |
| | Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats | Q64814751 |
| | Bilateral subthalamic nucleus stimulation for severe Parkinson's disease | Q70875241 |
| | Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus | Q71323710 |
| | Reduction of apomorphine-induced rotational behaviour by subthalamic lesion in 6-OHDA lesioned rats is associated with a normalization of firing rate and discharge pattern of pars reticulata neurons | Q71815637 |
| | Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements | Q73395693 |
| | Functional architecture of basal ganglia circuits: neural substrates of parallel processing | Q29618729 |
| | Formation and inactivation of endogenous cannabinoid anandamide in central neurons | Q29620558 |
| | CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum | Q31817073 |
| | Neuroprotective effect of chronic inactivation of the subthalamic nucleus in a rat model of Parkinson's disease. | Q33639858 |
| | Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. | Q33895436 |
| | Implication of the subthalamic nucleus in the pathophysiology and pathogenesis of Parkinson's disease. | Q33918872 |
| | High-frequency synchronization of neuronal activity in the subthalamic nucleus of parkinsonian patients with limb tremor | Q33920933 |
| | Functional changes of the basal ganglia circuitry in Parkinson's disease. | Q33924857 |
| | Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 |
| | Pharmacology of cannabinoid CB1 and CB2 receptors. | Q34442847 |
| | Brain cannabinoid systems as targets for the therapy of neurological disorders | Q34492167 |
| | Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 |
| | The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. | Q34786832 |
| | Distinct cannabinoid sensitive receptors regulate hippocampal excitation and inhibition. | Q35035824 |
| | CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 |
| | The subthalamic nucleus in the context of movement disorders | Q35579828 |
| | Opposing actions of chronic Delta9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation | Q35688747 |
| | The endocannabinoid system and its therapeutic exploitation | Q35876026 |
| | Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 |
| | Distribution of cannabinoid receptors in the central and peripheral nervous system. | Q36441196 |
| | Drug-induced dyskinesias | Q37505979 |
| | Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 |
| | Marijuana for parkinsonian tremor | Q41369366 |
| | Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates | Q41701358 |
| | The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats | Q42445636 |
| | Subthalamic nucleus cell firing in the 6-OHDA-treated rat: basal activity and response to haloperidol | Q42456220 |
| | Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the corticosubthalamic circuits. | Q42463451 |
| | Regulation of subthalamic neuron activity by endocannabinoids | Q42469292 |
| | Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen | Q42487505 |
| | Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment | Q42492786 |
| | The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism | Q42493851 |
| | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 |
| | Effects of 6-hydroxydopamine-induced severe or partial lesion of the nigrostriatal pathway on the neuronal activity of pallido-subthalamic network in the rat. | Q42510362 |
| | Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network | Q42510433 |
| | Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats | Q43581353 |
| | Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. | Q43611998 |
| | Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 |
| | Cannabinoids inhibit striatonigral GABAergic neurotransmission in the mouse | Q44084440 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 2 | |
| P921 | main subject | cannabinoids | Q422936 |
| P304 | page(s) | 379-389 | |
| P577 | publication date | 2010-10-20 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Nigrostriatal denervation changes the effect of cannabinoids on subthalamic neuronal activity in rats | |
| P478 | volume | 214 | |